CaaMTech is an Issaquah, WA–based psychedelic drug discovery company founded in 2017 and led by founder and CEO Dr. Andrew Chadeayne. The company focuses on engineering psychedelic drugs and has produced an extensive library of novel, analytically pure compounds. Those compounds are nearing advancement into human trials. CaaMTech intends to use newly raised funds to support its cross-disciplinary science program and expand its leadership team. The company plans to advance its foremost drug development candidates into human trials. As of September 2021, CaaMTech raised $22M in a Series A financing led by Noetic Fund.

Total raised

$22M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2021